MorphoSys Announces Clinical Milestone in Blood Disorders Program
News Jul 25, 2015
MorphoSys AG has announced that it has received a milestone payment from Novartis in connection with the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of blood disorders.
This becomes the eleventh therapeutic antibody made using MorphoSys's technologies that Novartis is evaluating in clinical trials. The associated milestone payment was booked in Q2 2015.
"With eleven therapeutic antibody programs in clinical development to date, our alliance with Novartis has resulted in a substantial drug candidate portfolio," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's news represents the second clinical milestone with our partners during the course of this year."
MorphoSys's collaboration with Novartis has resulted in eleven clinical programs to date, six of which are in Phase 1 development, with another four programs in Phase 2 and one in Phase 3.
In total, MorphoSys's proprietary and partnered clinical pipeline currently comprises 24 unique antibody molecules, which are being evaluated in more than 50 clinical trials.
Malaria Prevention: New Antibody Targets Unique Binding SiteNews
Scientists have discovered a human antibody that, when tested in mice, prevented malaria infection by binding a specific portion of a surface protein found in almost all strains of the malaria parasite worldwide.READ MORE
Huntsman Cancer Institute Joins National Clinical Trial Targeting AMLNews
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has been selected to participate in the Beat AML Master Trial, an innovative clinical trial sponsored by The Leukemia & Lymphoma Society (LLS). The clinical trial is testing several new targeted therapies for the treatment of patients with acute myeloid leukemia (AML). HCI is the only facility in the Mountain West offering this trial to AML patients.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
International Conference on Molecular Biology and Stem Cells
Aug 13 - Aug 15, 2018